ACTRN12610000134022已完成3 期
A multicentre trial of Tamoxifen to prevent breast cancer in women at increased risk of breast cancer.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 7,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 45 Years 至 70 Years（—）
- 性别
- Female
入选标准
- •Women must satisfy at least one of the entry criteria listed below.
- •A) Age 45-70 with at least one of the following:
- •1. Breast cancer in mother, sister or daughter diagnosed under the age of 50
- •2. Mother, sister or daughter with cancer in both breasts at any age
- •3. Any two first or second degree relatives (blood relatives) with breast cancer
- •4. Having no children, and with a mother or sister with breast cancer at any age
- •5. Having had a benign biopsy with proliferative disase and a mother, sister or daughter who developed breast cancer at any age
- •6. Having had a biopsy with lobular carcinoma in situ
- •7. Having had a benign biopsy with atypical ductal or lobular hyperplasia
- •8. Other equivalent risk to the above (to be confirmed by the Study Chairman
- •B) Age 40-44 with at least one of the following:
- •9. Any two first or second degree relatives (blood relatives) with breast cancer under the age of 50
- •10. Mother, sister, or daughter with breast cancer in both breasts under the age of 50
- •11. Having no children, and a mother or sister with breast cancer under the age of 40
- •12. Having had a benign biopsy with proliferative disease and a mother, sister or daughter with breast cancer under the age of 40
- •13. Having had a biospy with lobular carcinoma in situ
- •14. Having had a benign biopsy with atypical ductal or lobular hyperplaisa
- •15. Other equivalent risk to the above (to be confirmed by the study chairman)
- •C) Age 35-39 with at least one of the following:
- •16. Two relatives, mother, sister or daughter with breast cancer under the age of 50
- •17. Mother, sister or daughter with breast cancer in both breasts under the age of 40
- •18. Having had a biopsy with lobular carcinoma in situ
- •19. Other equivalent risk to the above (to be confirmed by the study chairman)
排除标准
- •a) Women with previous deep vein thrombosis or pulmonary embolus are excluded from the study
- •b) Women must not use hormonal contraception during the trial
- •c) Pregnant or at pregnacy risk
- •d) Life expectany less than 10 years
- •e) Currently being treated with anticoagulants
- •f) Previous cancer
研究者
相似试验
招募中
不适用
Tamoxifen preventive studyBreast cancerJPRN-jRCTs031200222akamura Seigo210
已完成
不适用
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 PolymorphismsBreast CancerCYP2D6 PolymorphismNCT01075802Western Sydney Local Health District121
已完成
4 期
Pharmacology of Adjuvant Hormonotherapy in Breast CancerHormono-depending Adjuvant Breast CancerNCT01127295Institut Claudius Regaud2,000
已完成
不适用
Clinical pharmacology of tamoxifen in breast cancer patientsPersonal history of malignant neoplasm of breastZ85.3RBR-7tqc7kFaculdade de Ciências Farmacêuticas de Ribeirão Preto
终止
2 期
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer RiskBreast Atypical HyperplasiaBreast Lobular Carcinoma in SituBreast Atypical Lobular HyperplasiaBreast CarcinomaNCT04570956Mayo Clinic65